Fulgent Genetics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fulgent Genetics, Inc. on November 9, 2021. The filing serves to announce the Company's financial results for the fiscal quarter ended September 30, 2021, and to disclose an updated investor presentation.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2021, have been issued.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure: The Company updated its investor presentation on November 9, 2021, available on its Investor Relations website and furnished as Exhibit 99.2.
- Legal Status of Information: Information in Items 2.02 and 7.01, including the press release and presentation, is furnished and not deemed "filed" under Section 18 of the Exchange Act. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2021 revenue, net income, and cash flow figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated business outlook and strategic guidance.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (FLGT) and exchange (Nasdaq Global Market) for the Common Stock.